Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03595813

Acronym

IMMUNO-SUP

Enrollment

135

Registered

2018-07-23

Start date

2018-01-29

Completion date

2025-06-25

Last updated

2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Malignant Neoplasm, Lung Cancer Metastatic, Non Hodgkin Lymphoma, Urologic Neoplasms

Keywords

Immune check point blockade, biomarkers, immunomonitoring

Brief summary

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

Interventions

PROCEDUREBlood sample collection

Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression

PROCEDUREBiopsy collection

Optional biopsy collection at baseline and progression

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade * Signed informed consent * Affiliated to(or beneficiary of) the French Social Security

Exclusion criteria

* Pregnant or breastfeeding woman or woman who does not apply effective contraception * Emergency * Vulnerable person or unable to provide informed consent * Emergency * Person unable to comply with required study follow up * Contraindication to the study procedure

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of Plasma immunosuppressive actors in patients treated with a Checkpoint inhibitor	4 months	Measure (by flux cytometry) and comparison of plasma immunosuppressive actors, between baseline and the 4th injection of an Immune Checkpoint inhibitor

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026